Because TRPV4 tends to be localized to cell types that are susceptible to glaucoma (RGCs, Müller glia, microglia, endothelial cells) (120–123), its targeting may achieve the quadfecta of IOP lowering, reduced neuroinflammation, reduced ischemia, and neuroprotection. This evidence concerns the gene TRPV4 and glaucoma.